BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 32, Issue 39
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis
Copyright: ©Author(s) 2026.
World J Gastroenterol. Oct 21, 2026; 32(39): 121372
Published online Oct 21, 2026. doi: 10.3748/wjg.121372
Table 1 Characteristics of included randomized controlled trials comparing potassium-competitive acid blocker vs proton pump inhibitor for Helicobacter pylori eradication (n = 30 studies, 32 comparisons)
Number
Ref.
Year
Country
P-CAB
PPI
Design
Regimen
Antibiotics
Days
Eradication success in P-CAB group (n = 4020)
Eradication success PPI group (n = 3619)
1Murakami et al[18]2016JapanVPZ 20 mgLPZ 30 mgRCT, DB, NITripleAMO + CLR7300/324 (92.6%)243/320 (75.9%)
2Maruyama et al[19]2017JapanVPZ 20 mgRPZ/LPZRCT, OLTripleAMO + CLR769/72 (95.8%)48/69 (69.6%)
3Sue et al[20]2018JapanVPZ 20 mgPPI mixRCT, OLTripleAMO + CLR748/55 (87.3%)39/51 (76.5%)
4Chey et al[3] (Triple)2022United States/EuropeVPZ 20 mgLPZ 30 mgRCT, DB, NITripleAMO + CLR14222/262 (84.7%)201/255 (78.8%)
5Chey et al[3] (Dual)2022United States/EuropeVPZ 20 mgLPZ 30 mgRCT, OLDualAMO14208/265 (78.5%)201/255 (78.8%)
6Choi et al[21]2022KoreaTPZ 50 mgLPZ 30 mgRCT, DB, NITripleAMO + CLR7110/175 (62.9%)106/175 (60.6%)
7Han et al[22]2023ChinaVPZ 20 mgRPZ 20 mgRCT, OLDualAMO10308/345 (89.3%)293/345 (84.9%)
8Huang et al[23]2023ChinaVPZ 20 mgESO 20 mgRCT, OLTripleAMO + Bi1438/40 (95.0%)32/40 (80.0%)
9Kim et al[24]2023KoreaTPZ 50 mgBQT (LPZ)RCT, DBBQTBi + MTZ + TC1484/105 (80.0%)82/106 (77.4%)
10Lu et al[25]2023ChinaVPZ 20 mgBQT (ESO)RCT, OL, NIBQTAMO + FUR + Bi1474/78 (94.9%)73/78 (93.6%)
11Peng et al[26]2023ChinaVPZ 20 mgModified BQT (PACB) (ESO)RCT, OL, MCDualAMO14142/158 (89.9%)128/158 (81.0%)
12Qian et al[27]2023ChinaVPZ 20 mgBQT (ESO)RCT, OLDualAMO (HD)10114/125 (91.2%)110/125 (88.0%)
13Wang et al[28]2023ChinaVPZ 20 mgBQT (RPZ)RCT, OLDualAMO1470/74 (94.6%)67/77 (87.0%)
14Chen et al[29]2024ChinaVPZ 20 mgILA 5 mgRCT, OL, NIDualAMO1438/45 (84.4%)38/45 (84.4%)
15Cheung et al[30]2024HKVPZ 20 mgBQT (ESO)RCT, OLDual/TripleAMO ± CLR1496/100 (96.0%)92/100 (92.0%)
16DWP14012[31]2024KoreaFXP 40 mgLPZ 30 mgRCT, DB, Ph3TripleAMO + CLR14184/220 (83.6%)166/213 (77.9%)
17Huang et al[32]2024ChinaVPZ 20 mgBQT (ILA)RCT, OL, MCDualAMO1096/103 (93.2%)81/101 (80.2%)
18Kong et al[33]2024ChinaVPZ 20 mgBQT (ESO)RCT, OL, NIDualAMO10158/184 (85.8%)155/184 (84.2%)
19Lee et al[34]2024KoreaTPZ 50 mgBQT (ESO)RCT, OL, NISeqAMO + CLR to MTZ10176/202 (87.1%)171/204 (83.8%)
20Liang et al[35]2024ChinaVPZ 20 mgModified BQT (PACB) (ESO)RCT, OL, MCTriple + BiAMO + Bi14251/300 (83.7%)247/297 (83.2%)
21Lin et al[36]2024ChinaTPZ 50 mgBQT (ESO)RCT, OLDualAMO14184/214 (86.0%)91/107 (85.0%)
22Tan et al[37]2024ChinaKVP 20 mgESO 20 mgRCT, DB, NIBQTBi + AMO + CLR14252/287 (87.8%)236/286 (82.5%)
23Zhou et al[38]2024ChinaVPZ 20 mgESO 20 mgRCT, OL, MCDualAMO10245/287 (85.4%)217/283 (76.7%)
24Cheng et al[39]2025ChinaTPZ 50 mgBQT (ESO)RCT, OL, MCDual/BQTAMO/Bi + CLR14138/160 (86.3%)115/149 (77.2%)
25Fan et al[40]2025ChinaVPZ 20 mgBQT (ESO)RCT, OLDualAMO14200/252 (79.4%)216/252 (85.7%)
26Fan et al[41]2026ChinaTPZ 50 mgBQT (ESO)RCT, OL, MCDualAMO1456/76 (73.7%)57/76 (75.0%)
27Han et al[42]2025ChinaVPZ 20 mgModified BQT (PACB) (ESO)RCT, OLTripleAMO + CLR14154/175 (88.0%)127/175 (72.6%)
28Park et al[43] (50 mg)2026KoreaTPZ 50 mgLPZ 30 mgRCT, DB, NITripleAMO + CLR14100/113 (88.5%)100/123 (81.3%)
29Park et al[43] (100 mg)2026KoreaTPZ 100 mgLPZ 30 mgRCT, DB, NITripleAMO + CLR14104/119 (87.4%)100/123 (81.3%)
30Shekeban et al[44]2025EgyptVPZ 20 mgSTT (ESO)RCT, OLDual/tripleAMO ± CLR1477/88 (87.5%)37/44 (84.1%)
31Tai et al[45]2025TaiwanVPZ 20 mgRPZ 20 mgRCT, OLDualAMO1453/61 (86.9%)49/60 (81.7%)
32Yan et al[46]2025ChinaVPZ 20 mgBQT (ESO)RCT, OL, MCBQTBi + DOX + MTZ14150/166 (90.4%)118/166 (71.1%)
P-CAB: Potassium-competitive acid blocker; VPZ: Vonoprazan; TPZ: Tegoprazan; KVP: Keverprazan; FXP: Fexuprazan; LPZ: Lansoprazole; RPZ: Rabeprazole; ESO: Esomeprazole; ILA: Ilaprazole; AMO: Amoxicillin; CLR: Clarithromycin; MTZ: Metronidazole; FUR: Furazolidone; DOX: Doxycycline; Bi: Bismuth; TC: Tetracycline; BQT: Bismuth quadruple therapy; STT: Standard triple therapy; RCT: Randomized controlled trial; DB: Double-blind; OL: Open-label; NI: Non-inferiority; MC: Multicenter; Ph3: Phase 3; HD: High-dose; Seq: Sequential; PACB: Proton pump inhibitor, amoxicillin, clarithromycin, bismuth.
Full Size Table
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.